This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A breakthrough gene-editing therapy for human immunodeficiency virus type 1 (HIV) infection has entered first-in-human testing in what is being called “a major milestone in the search for a cure for HIV/AIDS”. EBT-101, a CRISPR-Cas9 gene editing system delivered by adenovirus-associated virus vector serotype 9 (AAV9) has been administered to the first individual in a Phase I/II trial designed to establish its safety and efficacy.
It is the year 2030. You have just received the results from your whole genome sequencing test, offered through your public health provider, and discovered that you have a 75% chance of developing a rare form of cancer. But you are not panicking; your genomic data was automatically uploaded, with your permission, to your electronic health record (EHR), which is fully secured with blockchain technology.
Much like a house of mirrors, responsibility for understanding and mitigating cyber risk in healthcare is difficult to distinguish and often depends on who you ask, especially when it comes to non-enterprise systems and devices.
Moving from the ‘new normal’ to the ‘next normal’ and beyond, the landscape for pharma’s commercial operations continues to shift, with all stakeholders beginning to adjust to a post-pandemic world
AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.
Growing a sales team isn’t hard. Growing a sales team that’s confident, comfortable and successful in their role… now that’s a challenge. The effectiveness of any sales team starts with the sales leaders. It’s why many experts say any L&D spending should start (not end) with investing in your leaders. Simply adding more people to the team won’t deliver the scalability and dividends you’re looking for if your sales leaders aren’t willing to put
Rivus Pharmaceuticals’ Series B round will finance ongoing clinical development of its lead drug, a pill that targets mitochondria to increase caloric expenditure. CEO Allen Cunningham said the new cash comes on the heels of results from a mid-stage obesity study treatment with the Rivus drug led to fat loss while also preserving skeletal muscle.
Rivus Pharmaceuticals’ Series B round will finance ongoing clinical development of its lead drug, a pill that targets mitochondria to increase caloric expenditure. CEO Allen Cunningham said the new cash comes on the heels of results from a mid-stage obesity study treatment with the Rivus drug led to fat loss while also preserving skeletal muscle.
Pfizer has entered an agreement with Global Fund to deliver up to six million courses of its oral therapy, Paxlovid (nirmatrelvir tablets and ritonavir tablets), under the Covid-19 Response Mechanism (C19RM). The C19RM has been the main channel to support low- and middle-income nations in procuring Covid-19 therapies, personal protective equipment, tests and vital elements to bolster health systems.
Clarivate draws on Web of Science publication and citation data to produce an annual list of Citation Laureates – researchers of Nobel class whose high-impact contributions have transformed their fields and changed our world for the better. Every October, the world watches as the Nobel Assembly votes to confer their prestigious prizes. While people around the globe can’t help but speculate about who will be chosen, Clarivate is the only organization to use quantitative data in addition to qualit
As the U.S. healthcare industry continues to advance value-based care and population health, lab testing price transparency and payment integrity programs should be a priority.
Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.
Findings from the litifilimab trial, undertaken by Northwell Health’s Division of Rheumatology and The Feinstein Institutes for Medical Research, have been published in the New England Journal of Medicine and show promise for those who have been diagnosed with systemic lupus erythematosus (SLE). Sponsored by Biogen Inc., data from the phase 2 LILAC (Part A) clinical trial published this month shows that the experimental lupus therapy could reduce disease activity in the joints of patients, globa
Scientists at Shanghai Tongji University in China have created a face mask that can alert the wearer to the presence of respiratory viruses in the surrounding environment, including the viruses behind COVID-19 and influenza. The mask includes aptamers, which are short sequences of DNA or RNA that can bind to protein targets. When viral particles bind to the aptamers, ion-gated transistors boost the signal so that the mask can sensitively detect small amounts of virus.
These are the three changes health-tech needs to make to recreate Amazon, Uber or Venmo-like experiences in healthcare that will most accurately help to digitally replicate the humanized interactions that patients want:
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
At Climate Week NYC GSK presented its new Sustainable Procurement Programme, announcing a fresh agenda, outlining how they will support their suppliers to succeed in their bold environmental objectives: have a net zero climate impact and a net positive impact on nature. This is an important move, as many GSK suppliers do not have easy geographical access to green infrastructure or green financing.
Help Providers Win New Patients from Large Local Businesses with These Tactics. Large or dominant employers in your local communities are excellent targets of opportunity for new patients and cases. Most healthcare providers have local businesses that are (or could be) a source of new business. Whether it’s a company that's conveniently located across the street, or a dominant employer in the community, your providers want their business—here’s how you can help them win it.
A Biogen drug designed for a genetically defined form of amyotrophic lateral sclerosis led to patient improvement at a 12- month analysis, according to data now published in the New England Journal of Medicine. Biogen had already filed an application seeking FDA approval of the ALS drug, tofersen; a regulatory decision is expected by January.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
In a recent paper, researchers demonstrated the comparability of a green high performance liquid chromatography (HPLC) for the determination and screening of typical antipsychotic drugs both in bulk and pharmaceutical formulation. Antipsychotics are used to treat a variety of serious mental disorders including schizophrenia and bipolar disorder, in which manic states may require management with multiple drugs.
NEW YORK, NY, September 23, 2022: PM360 , a leading life sciences marketing industry trade publication, announced the winners of their 14 th annual Trailblazer Awards during an event held at Gotham Hall in New York City on Thursday, September 22, 2022. The awards recognize outstanding companies, CEOs, products, marketers, brand managers, and cutting-edge initiatives within the pharmaceutical, biotech, medical device, and diagnostics industries.
Cheryl Larson, president and CEO of Midwest Business Group on Health, said employers are worried that the consolidation of healthcare companies will lead to higher costs for employers and patients. She made her comments following McKesson’s announcement that it has agreed to acquire Rx Savings Solutions, but declined to speak specifically about the deal.
BeiGene’s BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine NHS use in England and Wales to treat Waldenström macroglobulinaemia (WM) – a rare form of non-Hodgkin lymphoma (NHL). The final appraisal document from health technology assessment (HTA) agency NICE says that Brukinsa can be used to treat WM in adults who have had at least one prior treatment, and only if bendamustine plus rituximab therapy is also suitable.
A cookieless future is on the horizon, so marketers across all industries are being forced to rethink their strategies and plan for the future. What does that entail?
As with my earlier post in this series on the overall role of peer review in the scholarly and scientific publishing process, for Peer Review Week 2022 we are reposting our pieces in this series. And little bit of updated information on the topics we covered: * Psychology, in particular, seems to have a replicability problem ; even outside of psych, everyone knows that bad papers are still getting published (and they may even have a discoverability advantage ). * Retraction Watch is still engage
Parth Desai, a principal with Flare Capital Partners, is one of three investor judges taking part in the Pitch Perfect competition at the INVEST Digital Health conference in Dallas September 28. He shares his perspective on the firm’s investment strategy, collaborating with startups, and more. Register today!
In today’s ultra-competitive markets, it’s no longer enough to wait for buyers to show obvious signs of interest. Instead, sales teams must be proactive, identifying and acting on nuanced buyer behaviors — often before prospects are fully ready to make a purchase. In this eBook from ZoomInfo & Sell Better, learn 10 actionable ways to use these buyer signals to transform your sales strategy and close deals faster.
New book sets the pharmaceutical industry on a course for bridging the patient centricity optimism gap. Bridging the gulf between patient centricity ambition and reality has never been more important for pharma – luckily, this seemingly insurmountable goal isn’t as far out of reach as many envision. That’s according to Sharon Suchotliff, patient centricity lead at consultancy firm ZS Associates, which has just published a book on the art of patient involvement.
The Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have announced that biosimilar medicines authorised in the European Union (EU) can now be interchanged with their reference medicine or an equivalent biosimilar product. Interchanging biosimilars is an acceptable practise already used by many Member States. However, the current lack of certainty whether interchangeability is acceptable EU-wide has prompted this decision.
Israeli medical device company Brainsway earned a positive coverage policy from Cigna for its deep transcranial magnetic stimulation to treat adult patients with OCD. Cigna joins the ranks of other major insurers who cover the device for OCD treatment — including Centene, Highmark, Blue Cross Blue Shield, Tricare and Palmetto GBA.
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content